News

The European Medicines Agency (EMA) has released findings from its Pilot Program on drug repurposing, marking a significant step toward establishing new regulatory pathways that could transform how existing medicines are developed for new therapeutic uses across Europe. Anticancer Fund has been a driving force behind this initiative, from its conceptual origins to supporting real-world implementation.

New research published in the journal Cancer Research provides evidence that adaptive therapy represents a promising strategy to address one of oncology's challenges: drug resistance. Anticancer Fund is supporting clinical trials that explore this treatment approach, which offers a different perspective on how to treat cancer.

The Anticancer Fund is now part of FORCE, a major European initiative supporting research on rare and hard-to-treat cancers. Alongside 13 non-profit partners from 11 countries, we’re working to bring better, evidence-based treatments to patients who urgently need them.

On International Clinical Trials Day, we’ve reached a milestone: more than 1.000 patients are participating in our 7 ongoing clinical trials across 31 countries. These numbers represent more than data — they represent progress, and lives. Discover how smart research is driving change.

We started a global trial, U-R-Immune Glioma, investigating whether Immune therapy can offer an alternative treatment for children and young adults with brain tumours. In collaboration with SickKids and CHEO in Canada.

We have uncovered alarming practices in private cancer clinics, where cancer patients are being charged tens of thousands of euros for unproven cancer treatments. We raised concerns about these dangerous practices to investigator journalists, to help protect cancer patients and and fight misinformation.